Navigation Links
New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
Date:5/27/2008

- FDA Approval Based on Updated Results Showing a 20% Reduction in the Risk of Death at Six Years and a 22% Improvement of Disease Free Survival at

Five Years, For Stage III Colon Cancer, Post Surgery -

BRIDGEWATER, N.J., May 28 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental new drug application (sNDA) to include six-year overall survival analysis from the MOSAIC trial in the Eloxatin(R) (oxaliplatin injection) prescribing information (PI). The new PI also reports five-year disease free survival (DFS) data in Stage III colon cancer patients treated following surgery to remove the primary tumor.

The MOSAIC trial results showed that after a median follow-up of six years, Stage III colon cancer patients treated with FOLFOX4 had a 20 percent reduction in the risk of dying compared to those treated with standard chemotherapy alone (hazard ratio of 0.80, confidence interval [0.65, 0.97] p=0.023). Stratified log-rank test was not adjusted for multiple comparisons. Also, Stage III patients treated with the Eloxatin-based regimen at 5 years were 22 percent less likely to relapse or risk of disease recurrence (HR=0.78 [CI: 0.65, 0.93], p =0.005) after 77 month follow-up.

"The MOSAIC six-year follow-up data demonstrate that as an adjuvant treatment for Stage III colon cancer, the Eloxatin-based regimen significantly lowered the risk of death and recurrence," said principal investigator Aimery de Gramont, MD, Oncology, Hospital Saint Antoine, Paris, France.

In the MOSAIC trial, neutropenia (decrease in the number of white blood cells) was the most frequently reported side effect, affecting 78.9% of patients. Neutropenia was complicated by fever or infection in only 1.8% of cases. Peripheral sensory neuropathy ("tingling or numbness" in the fingers or toes) occurred in 92.1% of patients treated with FOLFOX4. Half (48.2%) of the episodes were gra
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. ORTHO EVRA(R) Prescribing Information Updated
6. ImpactRx Tracks Decline in Zetia and Vytorin Prescribing
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
9. Initiation of Coverage Informational Review Issued by Scimitar Equity Research
10. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 According to Kalorama Information, electronic ... make Big Data in healthcare a reality, and this ... of the American Recovery and Reinvestment Act, the U.S. ... projects and penalties will start applying soon for use ... its complete study of the EMR industry, EMR ...
(Date:8/19/2014)... , Aug. 19, 2014  Regeneron Pharmaceuticals, Inc. (NASDAQ: ... conferences: , Sanofi and Regeneron will host an IR ... on Tuesday, September 2, 2014 , Baird 2014 ... September 3, 2014 , Citi,s 9 th ... Thursday, September 4, 2014 , Morgan Stanley Global ...
(Date:8/19/2014)... PARK, Calif. , Aug. 19, 2014   DelMar ... a protocol amendment to allow for expanded dosing in its ... and Drug Administration (FDA) and that a new cohort of ... clinical trial sites in the United States ... million have been raised through warrant exercise in two separate ...
Breaking Medicine Technology:Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7
... YORK, Nov. 17 Romeo and Juliette Laser ... hair removal center in New York City to own the ... leading developer and manufacturer of laser and light-based aesthetic treatment ... patented MultiPlex sequencing technology, is a highly versatile laser aesthetic ...
... , NEW YORK, Nov. 17 Engineer/pilot/attorney ... credit. They include technology that thwarts piracy in ... behind, devices to enhance airport security and even an ... interests that they have, indeed, found their match. ...
Cached Medicine Technology:Romeo and Juliette Laser Hair Removal Is First Center in New York City to Own Cynosure's New Elite MPX(TM) Laser System 2When Viruses (Including H1N1) and Bacteria are as Close as your Fingertips; VirWall's New Innovation Can Disarm Killer Keyboards 2
(Date:8/19/2014)... (PRWEB) August 20, 2014 Recently, iFitDress.com,a ... occasion outfits, has unveiled its new collection of ... made to expand the company’s global market. Each item ... to the company’s senior spokesman, customers that have specific ... at iFitDress.com. Now, all the brand new items are ...
(Date:8/19/2014)... Aug. 19, 2014 (HealthDay News) -- Lupus and ... as headaches and seizures, which can delay a ... Treatments for rheumatic diseases can also cause ... Loyola University Medical Center in Maywood, Ill. ... the joints and soft tissues, such as lupus, ...
(Date:8/19/2014)... Just back from Glasgow where he helped distribute thousands ... Commonwealth Games (July 23 – August 6), Pete Dwan is ... And the need for his work cannot be overstated. , ... 59 consumed Class A drugs within the last year. And ... (NPS) drugs considered to be “legal highs” until June 2014, ...
(Date:8/19/2014)... Warfarin, the longtime standard treatment for atrial fibrillation, ... anticoagulant drug marketplace including dabigatran, rivaroxaban, and apixaban. ... these novel oral anticoagulants (NOACs) into clinical practice. ... new anticoagulant prescriptions yet this represents 98% of ... The American Journal of Medicine . , ...
(Date:8/19/2014)... City, Utah (PRWEB) August 19, 2014 ... Benefits Solution, published a new guide on compliance ... Zane Benefits, small businesses want to offer employee ... health insurance is unsustainable. Additionally, there are new ... portability, guaranteed-issue, and lower costs. , The ...
Breaking Medicine News(10 mins):Health News:Discounted Pewter Evening Dresses For 2014 Unveiled By Company iFitDress.com 2Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:British Scientologist on a Mission to Save Youth from Drug Abuse 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3
... medications is associated with increased severity of erectile dysfunction, according ... British Journal of Urology International ., This study surveyed 37,712 ... taking various medications are likely to have more severe ED. ... multiethnic cohort of men ages 46 to 69 who are ...
... NJ . November 13, 2011. Kessler Foundation received a ... Geriatric Life Improvement. Anna Barrett, MD, director of Stroke ... to finding better ways to treat hidden disabilities that ... are pleased to receive this grant," said Rodger DeRose, ...
... By Serena Gordon HealthDay Reporter , MONDAY, Nov. ... warfarin need blood tests every four weeks to make sure ... suggests that some people could safely have those tests done ... isn,t an option for everyone on warfarin, just those who ...
... News) -- Drinking alcohol may be especially risky for young ... including having mothers, grandmothers or aunts with the disease, a ... Medicine in St. Louis examined data on more than 9,000 ... aged 9 to 15) through 2007. They focused on ...
... Indianapolis Wishard Health Services chief medical information officer, ... named one of America,s leading clinical informaticists by Modern ... Dr. Dexter is an associate professor of clinical medicine ... director of clinical applications at Wishard. "Dr. ...
... MONDAY, Nov. 14 (HealthDay News) -- Hearing loss affects ... far higher number than previously believed, researchers report. ... during National Health and Nutritional Examination Surveys (NHANES) from ... Organization,s definition of hearing loss (unable to hear sounds ...
Cached Medicine News:Health News:Erectile dysfunction increases with use of multiple medications 2Health News:Erectile dysfunction increases with use of multiple medications 3Health News:Kessler Foundation awarded stroke research grant by Wallerstein Foundation 2Health News:Warfarin May Need Less Monitoring for Some 2Health News:Warfarin May Need Less Monitoring for Some 3Health News:Drinking Risky for Women With Family History of Breast Cancer: Study 2Health News:Drinking Risky for Women With Family History of Breast Cancer: Study 3Health News:Indianapolis doc recognized as one of nation's top health info tech experts 2Health News:Indianapolis doc recognized as one of nation's top health info tech experts 3Health News:Hearing Loss Far More Common Than Expected 2
The ACMI TurboFlow 18 L and 10 L Insufflators provide rapid distention for all laparoscopic procedures. Eleven built-in safety features make insufflation reliable and dependable....
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
Bipolar forceps...
... An in vitro Nucleic Acid ... using Microplate Chemiluminescence for the ... (HPV) Types 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 ... Lowand High-Risk Groups in Cervical ...
Medicine Products: